Metastatic Left Colon and Rectal Cancer Treatment With Anti

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-01-01

Study Completion Date

2022-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Colorectal cancer ranks the second lethal cancer and third prevalent malignant tumour worldwide, Despite of different odern modalities for diagnosis,large number of cases diagnosed at metastatic advanced stage .

New treatment approach has been discovered habe been discovered making a huge revolution in metastatic colorectal cancer represented by targeted therapy including anti\_EGFR ,anti\_angiogenic and kinase inhibitors .

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer

NCT00506571

Colorecal Neoplasms Secondary

UNKNOWN PHASE2

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

NCT04607421

Neoplasms

ACTIVE_NOT_RECRUITING PHASE3

Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)

NCT05818267

Colorectal Cancer

RECRUITING NA

Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer

NCT03126071

Advanced Colorectal Cancer

UNKNOWN PHASE2

A Study of Response to Standard Treatment Before Surgery in People With Rectal Cancer

NCT06637462

Rectal Cancer Adenocarcinoma of the Rectum

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Retrospective study aims to evaluate the effect of EGFR expression in metastatic colorectal cancer and the outcome of treatment with anti\_EGFR targeted therapy between left colon and rectal cancer

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Colorectal Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. age above 18
2. Both sex
3. Performance status zero to one according to ECOG scale system
4. Histo-pathologial diagnosis adenocarcinoma of left colon or rectum.
5. Patients diagnosed with left colon and rectal cancer.
6. Patients eligible to receive chemotherapy (with renal and liver chemistry, and normal CBC.
7. Patients diagnosed with metastatic stage.
8. K-RAS wild type.

Exclusion Criteria

1. Second malignancy
2. Histo-pathological types other than adenocarcinoma.
3. Right colon cancer patients.
4. Patients refused receiving anti\_EGFR targeted therapy.
5. Patients with any abnormalities preventing to receive chemotherapy.
6. Early stages of colorectal cancer.
7. K-RAS mutant type.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No